---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107313"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:47:40.857463+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma restructures, cuts 20% workforce, and extends cash runway to 2H 2028

## Summary
- Initiated strategic pipeline prioritization, eliminating discovery research and reducing workforce by ~20%; expects ~$1.9M one-time charge in Q3 2025.
- Proforma cash and investments of $436.4M as of June 30, 2025, extending cash runway to 2H 2028 (previously 2H 2027).
- Q2 2025 R&D expenses $30.5M (up from $28.9M), G&A expenses $8.5M (up from $7.1M); no revenue reported.
- ORIC-944 Phase 1b data showed 59% PSA50 and 24% PSA90 responses; enozertinib (formerly ORIC-114) continues enrollment in NSCLC trials.

## SEC filing metadata
- accession: 0000950170-25-107313
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01, 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/0000950170-25-107313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/oric-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107313
- JSON: https://secwatch.observer/filing/0000950170-25-107313.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107313.txt

## Key facts
- Restructurings & Charges
  Oric Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.9 million affecting discovery research group (approximately 20% workforce reduction).
  - Type: restructuring
  - Charge: approximately $1.9 million
  - Affected area: discovery research group
  - Headcount: approximately 20% workforce reduction
  source text: On August 12, 2025, the Company initiated a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of its two lead clinical programs, ORIC-944 and ORIC-114. This initiative will result in a substantial decrease in preclinical research, primarily from the elimination of the Company’s discovery research group. This will result in an approximately 20% workforce reduction and the Company expects to incur a one-time cost of approximately $1.9 million primarily related to termination benefits, including severance and healthcare-related benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/0000950170-25-107313-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.